某三级甲等综合医院抗帕金森病药品第4批国家药品集中带量采购政策实施效果分析

Implementation Effect of the Fourth Batch of National-Centralized Drug Procurement Policy for Anti-Parkinson′s Disease Drugs in a Grade-A Tertiary General Hospital

目的分析第4批国家药品集中带量采购(以下简称国家集采)政策实施后某三级甲等综合医院抗帕金森病药品的使用现状。方法回顾性分析医院门诊药房第4批国家集采政策实施前(2020年5月1日至2021年4月30日)和实施后(2021年5月1日至2022年4月30日)抗帕金森病药品的使用数据,比较实施前后药品单价、总使用金额、用药频度(DDDs)、限定日费用(DDC)等的变化情况。结果实施后,抗帕金森病药品品规从8个增加到10个,单价平均下降10.09%;总使用金额由38203654.11元降至25951658.04元(降幅32.07%),集采中选品规使用金额为5170656.95元(占总使用金额的19.92%);DDDs平均下降5.56%,其中中选品规占该类药品DDDs的16.25%;DDC平均下降8.23%,共节省费用1477616.07元。结论第4批国家集采政策的实施,切实降低了帕金森病患者的用药经济负担。建议进一步优化抗帕金森病药品的一致性评价体系,以更有效地推动该类药品集采政策的实施。

Objective To analyze the use status of anti-Parkinson's disease drugs in a grade-A tertiary general hospital after the implementation of the fourth batch of national-centralized drug procurement(NCDP)policy.Methods The use data of anti-Parkinson's disease drugs in the outpatient pharmacy of the hospital before(May 1,2020 to April 30,2021)and after(May 1,2021 to April 30,2022)the implementation of the fourth batch of NCDP policy were analyzed retrospectively.The drug unit price,total consumption amount,defined daily doses(DDDs)and defined daily cost(DDC)before and after the implementation of the policy were compared.Results After implementation,the quantity of anti-Parkinson's disease drugs increased from eight to ten specifications,and the average unit price decreased by 10.09%.The total consumption amount decreased from CNY 38203654.11 to CNY 25951658.04(a decrease of 32.07%),and the consumption amount of selected specifications in the NCDP was CNY 5170656.95(accounting for 19.92%of the total amount).The DDDs decreased by 5.56%on average,of which the selected specifications accounted for 16.25%.The DDC decreased by 8.23%on average,saving a total of CNY 1477616.07.Conclusion The implementation of the fourth batch of NCDP policy reduces the financial burdens of medication for patients with Parkinson's disease.It is suggested that we should further optimize the consistency evaluation system of anti-Parkinson's disease drugs to promote the implementation of NCDP policy for such drugs more effectively.